BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23571420)

  • 21. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
    Shi Z; Wang AL; Jagannathan K; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
    J Psychiatry Neurosci; 2018 Jul; 43(4):254-261. PubMed ID: 29947607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
    Friedmann PD; Wilson D; Nunes EV; Hoskinson R; Lee JD; Gordon M; Murphy SM; Bonnie RJ; Chen DT; Boney TY; O'Brien CP
    J Subst Abuse Treat; 2018 Feb; 85():61-65. PubMed ID: 28236511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained-release naltrexone for alcoholism treatment: a preliminary study.
    Kranzler HR; Modesto-Lowe V; Nuwayser ES
    Alcohol Clin Exp Res; 1998 Aug; 22(5):1074-9. PubMed ID: 9726277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
    Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
    Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.
    Finigan MW; Perkins T; Zold-Kilbourn P; Parks J; Stringer M
    J Subst Abuse Treat; 2011 Oct; 41(3):288-93. PubMed ID: 21696912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial.
    Collins SE; Saxon AJ; Duncan MH; Smart BF; Merrill JO; Malone DK; Jackson TR; Clifasefi SL; Joesch J; Ries RK
    Contemp Clin Trials; 2014 Jul; 38(2):221-34. PubMed ID: 24846619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
    Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
    Hartung DM; McCarty D; Fu R; Wiest K; Chalk M; Gastfriend DR
    J Subst Abuse Treat; 2014 Aug; 47(2):113-21. PubMed ID: 24854219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
    Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
    J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-release naltrexone and harm reduction counseling for chronically homeless people with alcohol dependence.
    Collins SE; Duncan MH; Smart BF; Saxon AJ; Malone DK; Jackson TR; Ries RK
    Subst Abus; 2015; 36(1):21-33. PubMed ID: 24779575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.
    Sullivan MA; Bisaga A; Glass A; Mishlen K; Pavlicova M; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
    Drug Alcohol Depend; 2015 Feb; 147():122-9. PubMed ID: 25555621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.
    Springer SA; Di Paola A; Azar MM; Barbour R; Krishnan A; Altice FL
    Drug Alcohol Depend; 2017 May; 174():158-170. PubMed ID: 28334661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
    Crits-Christoph P; Markell HM; Gibbons MB; Gallop R; Lundy C; Stringer M; Gastfriend DR
    J Subst Abuse Treat; 2016 Nov; 70():50-57. PubMed ID: 27692188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
    Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
    Baser O; Chalk M; Rawson R; Gastfriend DR
    Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.
    Mann K; Vollstädt-Klein S; Reinhard I; Leménager T; Fauth-Bühler M; Hermann D; Hoffmann S; Zimmermann US; Kiefer F; Heinz A; Smolka MN
    Alcohol Clin Exp Res; 2014 Nov; 38(11):2754-62. PubMed ID: 25421512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A demonstration project implementing extended-release naltrexone in Los Angeles County.
    Cousins SJ; Denering L; Crèvecoeur-MacPhail D; Viernes J; Sugita W; Barger J; Kim T; Weimann S; Rawson RA
    Subst Abus; 2016; 37(1):54-62. PubMed ID: 26158698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence.
    Dunbar JL; Turncliff RZ; Hayes SC; Farrell CB
    J Stud Alcohol Drugs; 2007 Nov; 68(6):862-70. PubMed ID: 17960304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.